Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the UK / NCT06830798
Recruiting Phase 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798 · tracked via the Priya Life Science UK tracker
Sponsor
Alexion Pharmaceuticals, Inc
Phase
Phase 3
Started
2025-05-19
Last updated
2026-06-18

Condition(s) studied

Delayed Graft FunctionDGFKidney Transplant

Investigational drug(s) / intervention(s)

Ravulizumab →Placebo

Ravulizumab: Participants will receive ravulizumab via intravenous (IV) infusion.

Placebo: Participants will receive placebo via intravenous (IV) infusion.

Study summary

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * ≥ 18 years of age at the time of signing the informed consent * Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD) * A candidate for kidney transplant from: 1. Donation after Circulatory Death (DCD) donor 2. High-risk Donation after Brain Death (DBD) donor Exclusion Criteria: * Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification * Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.

Primary outcome measure(s)

  • Time to Freedom from Dialysis — Through 90 days post-transplant

Trial sites (130)

FacilityCityRegionStatus
Research Site Phoenix Arizona Recruiting
Research Site Los Angeles California Recruiting
Research Site San Francisco California Withdrawn
Research Site San Francisco California Recruiting
Research Site Stanford California Recruiting
Research Site New Haven Connecticut Recruiting
Research Site Jacksonville Florida Recruiting
Research Site Tampa Florida Recruiting
Research Site Atlanta Georgia Recruiting
Research Site Chicago Illinois Recruiting
Research Site Chicago Illinois Recruiting
Research Site Fairway Kansas Recruiting
Research Site Lexington Kentucky Recruiting
Research Site Kenner Louisiana Recruiting
Research Site Ann Arbor Michigan Recruiting
Research Site Detroit Michigan Recruiting
Research Site Minneapolis Minnesota Recruiting
Research Site St Louis Missouri Recruiting
Research Site Omaha Nebraska Recruiting
Research Site Livingston New Jersey Recruiting
Research Site New York New York Withdrawn
Research Site New York New York Recruiting
Research Site Durham North Carolina Recruiting
Research Site Philadelphia Pennsylvania Recruiting
Research Site Greenville South Carolina Recruiting
Research Site Nashville Tennessee Recruiting
Research Site Dallas Texas Recruiting
Research Site Houston Texas Recruiting
Research Site Charlottesville Virginia Recruiting
Research Site Richmond Virginia Recruiting
Research Site Seattle Washington Recruiting
Research Site Milwaukee Wisconsin Recruiting
Research Site Buenos Aires Argentina Recruiting
Research Site Buenos Aires Argentina Recruiting
Research Site Buenos Aires Argentina Recruiting
Research Site Capital Federal Argentina Not Yet Recruiting
Research Site Córdoba Argentina Recruiting
Research Site Adelaide Australia Recruiting
Research Site Brisbane Australia Recruiting
Research Site Camperdown Australia Recruiting

+ 90 more sites — see the full list on the official registry below.

On this site

📄 Ultomiris (ravulizumab) drug profile →

More Alexion Pharmaceuticals, Inc. trials in the UK

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy Recruiting
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa Active, not recruiting
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis Recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Active, not recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06830798 on ClinicalTrials.gov ↗ ← All trials in the UK